isavuconazole Articles
Edison analysts' take on Basilea outlook
10 September 2012
Basilea awarded $130 million in breach of contract arbitration with Johnson & Johnson; updates on isavuconazole program
30 November 2010
Basilea told Janssen-Cilag will stop Swiss sales of Zevetera; initiates Ph III testing of isavuconazole with Astellas
13 September 2010
Showing 1-4 of 4 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
